Metabolic Medicine Is Outgrowing Weight Management.

Medicine is organized largely by what happens downstream.

Cardiology treats heart failure and vascular disease. Sleep medicine treats obstructive sleep apnea. Hepatology treats steatohepatitis and fibrosis. Nephrology treats chronic kidney disease. Endocrinology treats diabetes. Obesity medicine treats excess adiposity and its complications.

These categories are useful. They organize expertise, research, training, and care. But they often describe where disease ultimately becomes visible—not necessarily where the biology that contributed to it began.

Increasingly, I feel that weight management is too narrow a frame for what is emerging in metabolic medicine.

Obesity is itself a chronic, biologically driven disease that deserves effective treatment. But its biology—and now its treatment—intersects with diseases far beyond the traditional boundaries of obesity care.

A threshold has been crossed

Modern incretin-based therapies have changed what is possible in obesity treatment.

In STEP 1, semaglutide 2.4 mg produced substantial average weight reduction at 68 weeks. SURMOUNT-1 subsequently demonstrated greater average reductions with tirzepatide at its highest studied dose.

These are trial results, not promises to individual patients. Real-world outcomes depend on persistence, tolerability, access, clinical support, and many other factors. Even so, the magnitude of pharmacologic weight loss has changed what patients and clinicians expect from medical therapy.

That magnitude understandably drew attention. What followed may prove even more consequential: the evidence moved beyond the scale.

The evidence now spans multiple organ systems

SELECT was an important inflection point. More than 17,600 adults with established cardiovascular disease and overweight or obesity—but without diabetes—were randomized to semaglutide or placebo. Major adverse cardiovascular events occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo, corresponding to a 20% relative reduction over a mean follow-up of approximately 40 months.

This was a cardiovascular outcomes trial, not simply a weight-loss trial.

Other studies have expanded the picture.

In obesity-related heart failure with preserved ejection fraction, semaglutide improved symptoms and physical function. SUMMIT subsequently showed that tirzepatide reduced the composite of cardiovascular death or worsening heart failure and improved health status.

In moderate-to-severe obstructive sleep apnea and obesity, tirzepatide substantially reduced sleep-disordered breathing. In MASH with stage F2 or F3 fibrosis, semaglutide improved steatohepatitis resolution and fibrosis-related histologic endpoints in the interim analysis of the ongoing ESSENCE trial. In people with type 2 diabetes and chronic kidney disease, FLOW demonstrated reductions in clinically important kidney and cardiovascular outcomes.

These trials differ in their populations, endpoints, and maturity. Taken together, however, they show that the clinical relevance of incretin therapy now extends across several organ systems.

The common thread is that these therapies are benefiting obesity-associated conditions shaped by metabolic dysfunction, chronic inflammation, and the mechanical consequences of excess adiposity.

Obesity affects hemodynamics, respiratory mechanics, insulin sensitivity, hepatic fat accumulation, inflammatory signaling, appetite and reward circuitry, and physical function. It follows that sustained weight loss of 15% or 20% can have profound effects throughout the body.

Effective treatment of obesity is itself a multisystem intervention.

Much of the explanation is straightforward. Substantial, sustained weight loss—and the accompanying improvement in metabolic dysfunction—can alter diseases that medicine has historically treated as separate problems.

Researchers are also asking, disease by disease, whether incretin signaling adds benefits beyond those expected from weight loss itself. These therapies influence glycemic regulation, vascular and renal physiology, ectopic fat, inflammatory signaling, appetite regulation, and other metabolic pathways. The evidence ranges from randomized outcomes data to observational associations and early mechanistic work, so the answer is unlikely to be uniform across conditions.

At minimum, the clinical conversation has moved beyond how much weight a treatment produces. The larger question is what happens to human health when we substantially alter metabolic biology that contributes to many of our most consequential chronic diseases.

Weight loss is central to that story, but it may not be the whole story. That is one reason the term weight management increasingly feels incomplete.

Weight matters, but it is not the whole outcome

Percentage weight loss remains an important clinical measure. It is measurable, understandable, and often closely associated with improvement in obesity-related disease.

But it cannot be the only endpoint.

For someone with established cardiovascular disease, the relevant outcome may be myocardial infarction, stroke, or cardiovascular death. For someone with HFpEF, it may be physical function, symptoms, and heart-failure events. For someone with sleep apnea, it may be improved sleep-disordered breathing and daytime function. For someone with MASH, it may be resolution of inflammation, regression of fibrosis, and ultimately prevention of cirrhosis and liver-related events.

For an older adult, preserving muscle, strength, nutrition, and independence may matter more than maximizing total weight loss. For a younger person with prediabetes, preventing diabetes may be more meaningful than reaching an arbitrary BMI. Another patient may care most about mobility, pain, fertility, quality of life, or the ability to participate fully in family and work.

Weight is also not synonymous with metabolic health.

Cardiorespiratory fitness is strongly associated with cardiovascular health and longevity. In observational cohorts, higher fitness is associated with lower mortality across BMI categories. That does not make excess adiposity irrelevant; it means that weight alone is an incomplete description of health.

For many patients, weight reduction can also be enabling. Less pain, improved mobility, greater exercise tolerance, and better sleep may lower barriers to physical activity. Successful treatment can create an opening to build the movement and fitness habits that contribute to durable metabolic health.

In that sense, weight loss may be a launching point rather than the destination.

Rather than asking only how much more weight we can help a patient lose, we should also ask what health outcome we are trying to improve and what treatment is needed to achieve it safely and durably.

That is a different clinical objective.

Our care systems are still organized downstream

The more I work at the intersection of clinical care, population health, and systems design, the harder it becomes to see these as separate medication questions.

Consider a patient with obesity, HFpEF, sleep apnea, prediabetes, and fatty liver disease.

That patient could now be offered the same therapeutic class through primary care, cardiology, sleep medicine, endocrinology, hepatology, or an obesity program. Each specialty has a legitimate interest in the patient’s outcome.

But when each condition is approached through a separate disease-specific lens, the patient does not necessarily experience integrated metabolic care.

They experience one biological problem fragmented across an organizational chart.

The practical challenge is not to decide which specialty owns the patient, nor is it to replace existing disciplines. Primary care and organ-specific specialists bring expertise that will remain essential.

What is missing is a stronger connective model: a shared metabolic frame that allows those disciplines to coordinate around the whole patient, the patient’s goals, and the outcomes that matter over time.

Specialty expertise can remain distributed, but the care should still feel coherent to the patient.

Metabolic care has to take the long view

Public discussion often centers on who receives treatment and how much weight they initially lose. The less settled question is what happens over years.

SURMOUNT-4 helps illustrate the problem. After an initial period of tirzepatide treatment, participants who continued therapy maintained and extended their weight reduction. Those switched to placebo regained substantial weight and experienced reversal of several cardiometabolic improvements.

The study does not answer every question about long-term treatment, but it reinforces the chronic biology of obesity and the difficulty of treating effective therapy as a temporary intervention.

Metabolic medicine therefore has to encompass more than treatment initiation. It must consider durability, changing patient goals, preservation of function, long-term safety, and the health outcomes that treatment is intended to sustain.

That longer view inevitably brings sustainability into the same clinical conversation. These therapies remain costly, increasingly prevalent, and potentially long-term. Their use matters not only to individual patients and clinicians, but also to employers, public programs, insurers, and health systems.

Access and stewardship are sometimes presented as opposing values. For therapies that may be used by millions of people over many years, responsible stewardship may be one of the conditions that makes durable access possible.

The goal is not simply to minimize drug spending or to expand treatment without accountability. It is to generate sustainable health value.

From headwaters to downstream health

I use the phrase upstream metabolic medicine to describe longitudinal care directed at metabolic processes that contribute to disease across multiple organ systems.

At its best, such care combines pharmacotherapy with nutrition, physical activity and fitness, behavioral science, procedural treatment, monitoring, and—where evidence supports it—increasingly precise approaches to selecting and adapting treatment.

The objective is not merely a lower number on the scale. It is better metabolic health, function, and longevity through earlier intervention in the biological processes that contribute to chronic disease, while using increasingly powerful therapies safely, equitably, and sustainably.

Different patients will need different combinations of care. Many will receive most of it through primary care. Some will receive care through telehealth or hybrid models. Others will need obesity specialists, endocrinologists, cardiologists, hepatologists, sleep physicians, bariatric surgeons, or multidisciplinary programs.

Metabolic medicine may eventually become a distinct discipline, a connective layer across existing specialties, or something in between. The immediate need is to recognize the work before us.

I live and work in Minnesota, home to the headwaters of the Mississippi River.

At its beginning, the river bears little resemblance to the enormous system it eventually becomes. Yet what happens upstream can profoundly influence what follows downstream.

The analogy has limits. Human metabolism has no single upstream pathway, no single cause of chronic disease, and no therapy that replaces nutrition, physical activity, fitness, behavior, environment, procedural treatment, or social context.

Still, the metaphor has stayed with me.

We are gaining the ability to intervene earlier and more powerfully in biological processes that influence disease across multiple organ systems. Now we have to determine which evidence is mature enough to act on, which outcomes matter for which patients, and how to translate scientific progress into responsible care at scale.

The future is not simply weight management with stronger drugs.

It is metabolic medicine: treating upstream biology, measuring downstream health, and building care systems capable of doing both.

Selected evidence

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183.
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232. doi:10.1056/NEJMoa2307563.
4. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069–1084. doi:10.1056/NEJMoa2306963.
5. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392:427–437. doi:10.1056/NEJMoa2410027.
6. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193–1205. doi:10.1056/NEJMoa2404881.
7. Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. N Engl J Med. 2025;392:2089–2099. doi:10.1056/NEJMoa2413258.
8. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121. doi:10.1056/NEJMoa2403347.
9. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331:38–48. doi:10.1001/jama.2023.24945.
10. Weeldreyer NR, et al. Cardiorespiratory Fitness, Body Mass Index and Mortality: A Systematic Review and Meta-Analysis. Br J Sports Med. 2025;59:339–346. doi:10.1136/bjsports-2024-108748.